{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-027949","form_type":"8-K","ticker":"MYO","cik":"0001369290","company_name":"MYOMO, INC.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.969605+00:00","generated_at":"2026-06-05T01:18:37.246854+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Myomo Q4 revenue $4.8M (+18% YoY), backlog record 230 units, guides FY2024 rev $28M-$30M","bullets":["Q4 product revenue $4.756M (+18% YoY); recognized 107 MyoPro units (+6%).","Net loss $2.5M ($0.07/shr) vs $2.2M ($0.29/shr) in Q4 2022; adjusted EBITDA -$2.1M.","Record backlog 230 units (+40% YoY), including 44 Medicare Part B patients receiving rental payments or qualified.","Q1 2024 revenue guidance $4.1M-$4.3M; full year 2024 revenue target $28M-$30M with operating cash flow breakeven targeted by Q4.","CMS finalized HCPCS fees for MyoPro codes L8701 ($33,480.90) and L8702 ($65,871.74) effective April 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-027949","json":"https://secwatch.observer/filing/0000950170-24-027949.json","markdown":"https://secwatch.observer/filing/0000950170-24-027949.md","text":"https://secwatch.observer/filing/0000950170-24-027949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024027949/0000950170-24-027949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024027949/myo-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:18:37.246854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69d8f11c51868a376fea71f406e991bb5fd31a81","claim":"MYOMO, INC. reported the three months and year ended December 31, 2023 results: revenue $4.8 million, net income $0.07 per share. Guidance initiated.","evidence_excerpt":"by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2023 Financial Results Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received in Q4, up 87% over the prior","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024027949/0000950170-24-027949-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and year ended December 31, 2023"},{"label":"Revenue","value":"$4.8 million"},{"label":"Net income","value":"$0.07 per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}